Insys Therapeutics (INSY) Receiving Somewhat Positive Press Coverage, Analysis Finds
News headlines about Insys Therapeutics (NASDAQ:INSY) have trended somewhat positive on Sunday, according to Accern. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insys Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.2100023947098 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern’s scoring:
- INSYS Therapeutics, Inc. (INSY) Expected to Announce Earnings of -$0.15 Per Share (americanbankingnews.com)
- Varying Stocks: INSYS Therapeutics, Inc., (NASDAQ: INSY), Warrior Met Coal, Inc., (NYSE: HCC), China Yuchai … – Stocks In The News (press release) (tradingnewsnow.com)
- Stocks on the Run: INSYS Therapeutics, Inc., (NASDAQ: INSY), Compania de Minas Buenaventura SAA, (NYSE: BVN … – Stocks In The News (press release) (tradingnewsnow.com)
- Insys Therapeutics, Inc. 2017 Q3 – Results – Earnings Call Slides (seekingalpha.com)
- Insys Therapeutics, Inc. (INSY) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
Insys Therapeutics (NASDAQ INSY) traded down $0.05 on Friday, hitting $5.16. The stock had a trading volume of 485,500 shares, compared to its average volume of 907,903. Insys Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.02.
INSY has been the topic of several research analyst reports. Zacks Investment Research cut Insys Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Jefferies Group LLC reduced their target price on Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $14.00 target price on shares of Insys Therapeutics in a research note on Wednesday, October 11th. TheStreet cut Insys Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, August 21st. Finally, BidaskClub cut Insys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $9.38.
TRADEMARK VIOLATION NOTICE: “Insys Therapeutics (INSY) Receiving Somewhat Positive Press Coverage, Analysis Finds” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/insys-therapeutics-insy-receiving-somewhat-positive-press-coverage-analysis-finds/1698470.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.